Introduction
The possibility to surgically replace a damaged aortic valve represents a significant advantage for the majority of the patient population affected by severe aortic stenosis, which today is estimated at between 3% and 4% of patients aged >75 years. 1 Surgical aortic valve replacement (SAVR) has excellent outcomes and is associated with low operative morbidity and mortality in patients with low surgical risk. 2 Transcatheter techniques and technologies have expanded the population eligible for valve replacement to patients deemed inoperable or at an extremely high surgical risk. In the last few years, transcatheter aortic valve implants (TAVIs) have gained popularity and have been used to treat patients at lower surgical risk.
which reduce operative time and risk, while facilitating minimally invasive surgical approaches. 4 TAVIs and SAVR have been compared in several clinical trials, which have been pooled in meta-analyses, 5, 6 indicating substantial equivalence in terms of mortality and a different profile in the adverse effects. When used to inform economic analyses, these results led to estimates of significantly higher costs with TAVIs, coupled with a slight increase (0.2-0.4 quality-adjusted life-years [QALYs]) in quality-adjusted life expectancy, yielding incremental cost-effectiveness ratios (ICERs) around 50,000 $/QALY, which can be considered acceptable. 7, 8 The allocative efficiency of conventional AVR has also been compared with SU-AVR in developed countries, and both a modeling study 9 and three single-center real-life experiences [10] [11] [12] found that sutureless bioprostheses consistently outperformed traditional valves, as a consequence of faster recovery, made possible by reduced ischemic insults due to shorter cross-clamping time and increased recourse to a minimally invasive approach.
In contrast, a focused literature review revealed that the comparative economics of TAVIs and SU-AVR have not yet been assessed in a formal cost-effectiveness study, albeit having been explored in a single-center propensity-matched study. 13 The aim of the present work was to thoroughly assess the incremental cost-utility of using SU-AVR instead of TAVIs for the treatment of an intermediate-and high-risk patient population in need of aortic valve substitution.
Methods
The cost-utility analysis was conducted by conceptualizing, developing, and feeding a simulation model integrating baseline outcomes of the target population, relative effectiveness estimates, and local unit cost data pertinent to the analyzed settings.
Model structure
A two-step model was built in Microsoft Excel 2013 to assess the cost-utility of SU-AVR using the Perceval ® bioprosthesis vs TAVIs in intermediate-to high-risk patients.
The in-hospital pathway of each patient undergoing SU-AVR or TAVIs was simulated using a patient-level discrete event simulation (DES) structure, while a cohort Markov model with monthly cycles was chosen to describe the lifetime evolution for patients discharged alive from the hospital (Figure 1 ).
The DES technique seems preferable to the Markov methodology in representing clinical conditions that are neither chronic nor characterized by recurrent events occurring at fixed time intervals, as in hospitalized patients. Each iteration of the simulation represents a unique patient who is sent simultaneously through both arms of the model (SU-AVR and TAVIs). The parameters of each iteration are drawn from distributions representing the interindividual variability in outcomes of the simulated population. The simulation steps are qualitatively common for both treatment arms, which differ in the probability of the events considered and for the time-to-event distributions. The cohort simulated in the Markov model uses the output of the in-hospital phase as starting point. In each cycle, patients can be alive, can be at a risk of experiencing rehospitalization, or may die; for patients who developed chronic kidney insufficiency during the first phase of the model, lifetime dialysis was simulated.
The hospital perspectives of six different countries (the US, Germany, UK, France, Italy, and Australia) were adopted when calculating costs associated with each state and evaluating the differential economic impact of SU-AVR vs TAVIs; all costs were updated till 2017 using country-specific inflation indices. 14, 15 Half-cycle correction and a 3.5% annual discount rate were applied to both costs and outcomes after hospital discharge. 16 
Clinical inputs in-hospital
Clinical outcomes and resources consumption have been modeled directly for TAVIs, while in the SU-AVR arm they are obtained by applying relative treatment effects.
Event probabilities for TAVIs were estimated by pooling together the most recently published evidence from observational studies (Table S1) ; length of stays (LOSs), both in ICU and in hospital, were derived from the SOURCE 3 Registry, 17 as no observational studies reporting these data were retrieved; median and interquartile range (IQR) were converted into mean and SD according to the formulas proposed by Wan et al. 18 For each patient, events were simulated using Bernoulli distributions, while LOSs were sampled from a gamma distribution fitted on the reported mean and SD. No data were found on the incidence of permanent renal dysfunction; to take into account the impact of lifetime dialysis in the model, it was assumed that 10% of acute kidney injuries develop into chronic renal dysfunction (the impact of such assumption was investigated in sensitivity analyses).
From our focused literature review, no randomized clinical trials comparing TAVIs with SU-AVR are available; however, a series of propensity score matched comparative analyses have been published. These have been pooled in at least four meta-analyses, with comparable results on the common outcomes. [19] [20] [21] [22] Among these, the recently published work by Meco et al 21 investigated the comparison on a more complete set of outcomes, besides being one of the most updated we identified, and was therefore selected as our source for the relative treatment effects.
This meta-analysis compared efficacy and safety outcomes in 731 SU-AVR patients (95% implanted with Perceval and 5% with 3f Enable) and 731 matched TAVI patients. Tables S2 and S3 summarize the characteristics of the enrolled population and analyses on postoperative outcomes. We reperformed the same analysis to obtain relative risk as effect estimate, more suitable for the simulation model than the originally reported ORs; only statistically significant comparisons were considered in the model. The comparison of hospital LOSs was also included, even if not analyzed in Meco et al, 21 as three of the six selected papers reported this outcome, which is highly relevant for economic evaluation purposes. Table S4 shows the data.
The number of red blood cell (RBC) units transfused during the hospitalization of patients undergoing TAVIs was estimated from Ussia et al, 23 assuming a gamma distribution (data reported: 22.1% of patients requiring two to three units, 6 .1% of patients requiring more than three units); it resulted in 0.86±1.22 RBC units transfused. For patients undergoing SU-AVR, the number of RBC units was estimated starting with blood loss during surgery and ICU stay reported in Pradelli et al, 9 assuming one unit transfused every 500 mL of blood loss; it results in 1.22±0.22 RBC units transfused.
long-term
Evidence from Kodali et al 24 showed that mild-to-severe paravalvular leak (PVL) is an independent predictor of overall survival (OS) after TAVIs or SAVR (HR =2.11, P<0.001). Following the same approach for the health technology assessment of TAVIs in the UK, 25 we performed a Weibull regression on data extracted from the Kaplan-Meier OS without PVL from Kodali et al 24 and then applied the HR of 2.11 to obtain the OS curve for patients developing PVL during hospitalization (Figure 2 ). This approach was applied for patients treated with both TAVIs and SU-AVR. A further mortality HR equal to 2.005 was applied for patients developing permanent renal dysfunction. 26 Evidence from Ussia et al 23 and Barbanti et al 27 was used to fit a Weibull model for hospitalization-free survival (HFS) after TAVIs; for SU-AVR patients, an HR elaborated from Santarpino et al 28 was applied: HFS =86.5% with SU-AVR vs 54.1% with TAVIs after a mean follow-up of 18.9±10.1 months, resulting in an HR of 0.24 ( Figure 3) . Reasons for rehospitalizations differed between compared arms; stroke was responsible for 17.1% of episodes for SU-AVR vs 9.5% with TAVIs, pacemaker implantation (PMI) accounted for 54.1% of readmissions in SU-AVR patients vs 19.5% after TAVIs, while heart failure, vascular complications, and PVL leading to valve explant represented 28.8% of cases in the SU-AVR group vs 71% with TAVIs; data were taken from Fischlein et al 29 for SU-AVR and Barbanti et al 27 for TAVIs.
Utilities
Treatment efficacy was measured using QALYs calculated by multiplying the duration in a particular health state by the utility weight for that health state. The quality weight associated with a patient who is alive after discharge was calculated based on the estimated utility by New York Heart Association (NYHA) class 30 (Table S5 ) applied to the proportion in each NYHA class, estimated by pooling the most recent clinical evidence for Perceval and TAVIs. [31] [32] [33] [34] [35] The baseline (after discharge) NYHA distribution is same for both treatments to avoid introducing bias, as at hospital admission candidates for TAVIs had a slightly more favorable NYHA status than those for SU-AVR. Subsequently, changes in NYHA class distribution were different in the two arms, according to the treatment-specific evidence; after 4 years, no further change in NYHA was assumed as no data were available in the literature ( Figure 4 ).
In cases of rehospitalization, specific disutility 30 was applied according to the number of hospitalizations, assuming that 80% of patients undergo one hospitalization, 15% two hospitalizations, and 5% three hospitalizations (this assumption was investigated in the sensitivity analysis). Furthermore, in case of lifetime dialysis, a decrement of 0.22 in utility was applied 36 (Table S5) .
Costs
Costs considered in the analysis are direct health care costs, encompassing both in-hospital and long-term costs (Table 1) , in order to adopt a comprehensive third-party payer cost 
sensitivity analysis
Different sensitivity analyses were performed to take into account uncertainties about input parameters (probabilistic 
Notes:
a Estimated by applying the ratio between TaVis and Perceval operating room costs reported in santarpino et al 13 as it is the only analysis that reported both costs in the same structure. Calculated as the mean of full-sternotomy (Fs), minimally invasive (Mis), and concomitant (COnC) procedures estimated in Pradelli et al 9 weighted for the frequencies of Fs (41%), Mis (26%), and COnC (33%) reported in shrestha et al. 39 c Estimated as the mean between germany and italy. Estimated by applying the ratio between TaVis and Perceval diagnostic costs reported in santarpino et al 13 as it is the only analysis that reported both costs in the same structure.
e Market values.
f Calculated as the cost of operating room plus the cost of device for the 2.0% of patients who need a second valve implant. [47] [48] [49] The superscript numbers represent reference citations. Abbreviations: iCU, intensive care unit; PMi, pacemaker implantation; RBC, red blood cell; RRT, renal replacement therapy; sU-aVR, sutureless aortic valve replacement; TaVis, transcatheter aortic valve implants. sensitivity analysis [PSA]) and to investigate the impact of single variation on results (deterministic sensitivity analysis [DSA] ).
In the PSA, the simulation was repeated 1,000 times sampling all the key parameters from appropriate distributions fitted on mean and SE, where available. The joint distribution of cost and QALY (ie, the 1,000 resulting simulations) was shown in the incremental cost-effectiveness plane; furthermore, the 95% confidence ellipse was provided. In the DSA, parameters were varied one by one within their 95% CIs or by ±20% of baseline values (if CIs were not available). A tornado diagram was used to represent the effect of variation of input parameters on the outcomes. Tables S6-S9 list all the parameters used in the sensitivity analyses.
Results
In-hospital mortality for SU-AVR is lower than for TAVIs (4.1% vs 7.0%) with an analogous improvement in the lifetime survival (5.51 vs 4.26 life-years); patients discharged alive after AVR with SU-AVR live 1.25 years more than those undergoing TAVIs (Table 2 ). In addition, quality-adjusted life expectancy is higher with SU-AVR, with a mean gain of 1.14 QALYs.
Patients undergoing SU-AVR experience more reoperations (11.3% vs 4.7%) and stay three days more in hospital (10.56 vs 7.33) than those undergoing TAVIs; in contrast, SU-AVR is associated with lower rates of stroke (1.2% vs 2.3%), major postoperative vascular complications (0.4% vs 7.7%), and PVL (8.9% vs 54.4%). Long-term results also show a lower rate of rehospitalization (32.5% vs 44.2%). Table 2 lists all results.
Total costs both for SU-AVR and for TAVIs vary in the six analyzed countries (Table 3) due to different economic inputs, but a similar trend can be identified in the incremental analysis: Hospital costs for SU-AVR are slightly higher than those for TAVIs, excluding device costs; comparing all costs in dollars, the incremental cost ranges from $205 in Italy to $5,276 in Australia ( Figure 5 ). This increase is completely offset when device costs are considered, resulting in total hospital savings of about $2,500-$18,000 in favor of SU-AVR. Despite the higher survival with SU-AVR, long-term costs are generally lower than those for TAVIs. Considering total cost (in-hospital and long-term), SU-AVR is dominant with respect to TAVIs as it is more effective (+1.14 QALY) and less costly (savings of $4,000-$21,000).
Results from PSA confirm the main analysis, with 95% confidence ellipse lying completely (almost for France) in the dominance region of the cost-effectiveness plane ( Figure 6 ).
Effectiveness is mostly influenced by the HR of OS and by the time horizon ( Figure 7) ; SU-AVR also remains more effective than TAVIs for the lowest hypothesized effect of PVL on long-term survival (+0.70 QALY) and for a short time horizon simulation (+0.43 QALY at 5 years). The economic impact is mainly affected by device and operating room costs ( Figure 8 ). Even when reducing the economic gap between device or operating room costs, SU-AVR still saves costs compared with TAVIs.
Discussion
In this cost-utility analysis, we compared SU-AVR vs TAVIs in intermediate-and high-risk patients. We used a two-step modeling process consisting of a patient-level DES to simulate the in-hospital phase and a cohort Markov model to estimate the long-term consequences after hospital discharge. Clinical outcomes (both in hospital and after discharge) were determined from observational studies of TAVIs, while the outcomes for SU-AVR arm were derived by applying relative effects from a published meta-analysis 21 or from KaplanMeier analysis. 24 A surgical approach with a sutureless valve was more effective than TAVIs, with a significant reduction in 30-day mortality (−2.9%, IQR: [−3.7] -[−2.1]) and significant gains in survival (+1.25 years, IQR: 1.03-1.44) and quality of life (+1.14 QALY, IQR: 0.98-1.31). Furthermore, the total cost, including the cost of devices, rehospitalizations, and lifetime dialysis, was lower with SU-AVR than with TAVIs, with savings ranging from $4,000 to almost $21,000; these variations were due to differences in the cost structures in the six countries.
In general, our results are consistent with the other estimates in the literature, in terms of both cost-utility and the components of cost and effectiveness: TAVIs appear to be more costly than SAVR, with a slight gain in QALYs, yielding an acceptable but uncertain ICERs; SU-AVR is estimated less costly and more effective than SAVR; it is therefore not unexpected that SU-AVR economically outperforms TAVIs. Total hospital cost (device cost included) estimated for the US is similar to the total cost observed in a sample of 4,083 TAVIs occurring between January and December 2012; 78 the median cost for hospitalization resulted in a cost of $50,200 (IQR: 39,800-64,300) compared with our mean estimate of $52,727 (IQR: 51,518-53,806). The in-hospital cost and the cost consequences of TAVIs were evaluated for high-risk patients in the UK in a cost-effectiveness analysis vs SAVR; 25 short-term costs estimated for TAVIs (procedure, hospital stay, and adverse events) amounted to £25,079, which is comparable to our estimate (£26,032, IQR: 25,437-26,515); total costs were slightly lower (£27,833 vs £30,511, IQR: 29,886-32,308), since only follow-up appointments were considered and the National Health Service tariff for cardiac valve disorder (lower than our estimates) was used for the cost of rehospitalizations. Despite the longer time horizon considered in the model (25 years), the total quality of life estimate was lower than ours (2.853 vs 3.44 QALY) as a high-risk population was simulated; 6 months after discharge, <80% were in NYHA Class I or II, while in our simulation almost 90% were in these classes. During the last Transcatheter Cardiovascular Therapeutics meeting held in Denver in 2017, the results from the PARTNER 2A and Sapien-3 intermediate risk trials were presented. 79 In-hospital costs ranged between $54,256 and $61,433 vs $52,727 in our analysis, while follow-up costs were significantly higher than ours: $26,861 and $46,284 vs $16,663, probably because almost 70% of patients were rehospitalized in the first year, while according to the hospitalization-free survival curve used in our model <10% experienced hospital readmission for cardiac reasons. In the recently published cost-utility analysis from the Canadian health care perspective by Tam et al, 8 based on the PARTNER 2 trial, total costs for TAVIs also compare reasonably well with our estimates, both in magnitude and in composition ($47,000, of which $40,000 is for the index hospitalization).
A previous cost analysis estimated the cost of SU-AVR according to different surgical approaches (minimally invasive, full sternotomy, and concomitant) in Germany, UK, France, and Italy. 9 The total hospital costs without considering the cost of the sutureless valve were very similar to our results: €14,130-€17,300 for Germany (€14,598 in our analysis), £14,610-£17,950 for UK (£12,846 in our analysis), €15,640-€18,810 for France (€16,385 in our analysis), and €13,810-€16,740 for Italy (€16,447 in our analysis). The difference in the UK is most likely due to the low daily ICU and ward costs used in this analysis.
The only cost analysis comparing SU-AVR with TAVIs found in literature was the paper of Santarpino et al; 13 in this propensity score match analysis, 102 patients undergoing SU-AVR were matched and compared with 102 patients undergoing Abbreviations: nYha, new York heart association; Os, overall survival; PVl, paravalvular leak; QalY, quality-adjusted life-year; RR, relative risk; sU-aVR, sutureless aortic valve replacement; TaVis, transcatheter aortic valve implants.
HR OS (PVL vs no PVL)
Delta QALY-SU-AVR vs TAVI TAVIs in Germany, and the hospital costs both including and excluding the device costs were quite similar to those obtained in our analysis: €22,451 and €16,148 including and excluding the device costs, respectively, for SU-AVR (€20,394 and €14,598 in our analysis) and €32,877 and €14,164 including and excluding the device costs, respectively, for TAVIs (€25,355 and €14,335 in our analysis). The difference in inhospital cost including device cost is due to a higher device cost used in the analysis (almost €19,000 vs €11,000 in our model).
limitations
The main limitation of the present study is the use of common clinical parameters for all simulated countries, as hospital policies could be different in the US, Europe, and Australia (eg, different ICU or hospital LOSs). However, observational studies used as references recruited patients from the US, Italy, France, Germany, UK, Canada, Israel, Finland, Switzerland, and Spain; hence, regional variability should be taken into account. Figure 8 Tornado diagram of cost differences (sU-aVR vs TaVis) for the six countries considered in the analysis: Blue bars (min) represent cost differences for the minimum value of each parameter and orange bars (max) represent delta cost for the maximum value of each parameter. Abbreviations: OR, operating room; Os, overall survival; PVl, paravalvular leak; PMi, pacemaker implantation; RR, relative risk; sU-aVR, sutureless aortic valve replacement; TaVis, transcatheter aortic valve implants.
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